Today's Top SOA Links
From the Wires
Free Research Reports on ADT, CHK, MTOR and VRTX Issued by the Bedford Report
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit
By: Marketwired .
Jan. 31, 2013 08:45 AM
NEW YORK, NY -- (Marketwire) -- 01/31/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.
ADT Corp. (NYSE: ADT) shares surged 4.7 percent on nearly 5 million shares traded after reporting strong quarterly results. The company reported a net income of $105 million for the fiscal first quarter, a year-over-year increase of 12.9 percent.
Find out more about ADT including full access to the free equity report at: www.BedfordReport.com/ADT
Chesapeake Energy Corporation (NYSE: CHK) spiked sharply in Wednesday trading on nearly five-times the average daily volume Wednesday. The company reported that Chief Executive Officer and President, Aubrey K. McClendon, has agreed to retire from the company on April 1, 2013.
Find out more about Chesapeake Energy including full access to the free equity report at: www.BedfordReport.com/CHK
Meritor Inc. (NYSE: MTOR) shares fell as much as 16 percent, its biggest drop in over a year, on nearly four-times the average daily volume Wednesday. The company reported sales in the fiscal first quarter declined 23 percent year-over-year to $891 million. Results were affected by "weaker than expected market conditions outside North America" stated President and CEO Chip McClure.
Find out more about Meritor including full access to the free equity report at: www.BedfordReport.com/MTOR
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares declined 3.4 percent on nearly 3 million shares traded Wednesday. The company reported revenues in the fourth quarter declined 41 percent to $334.0 million in the fourth quarter, the steep drop was largely due to slowing sales of their hepatitis C drug Incivek.
Find out more about Vertex Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/VRTX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.
A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week